Executive Cardiac Screening That Changed a CEO's Life.
A corporate wellness program through WhiteGloveMD identified silent heart disease in a Fortune 500 executive.
This is a composite narrative based on common clinical scenarios. Patient details have been anonymized and combined for educational purposes. Individual results vary based on specific clinical circumstances.
A Fortune 500 company engaged WhiteGloveMD for executive cardiac screening as part of their C-suite wellness program. A 57-year-old CFO — who ran marathons and had no symptoms — underwent comprehensive evaluation including advanced lipid panel, coronary calcium scoring, and stress echocardiography.
What our Heart Team found.
Despite his fitness, his coronary calcium score was 680 (extremely high for his age), placing him above the 99th percentile. His Lp(a) was elevated at 180 nmol/L — an inherited risk factor not routinely tested. Stress echocardiography revealed a subtle wall motion abnormality. Subsequent catheterization showed 80% stenosis of the LAD and 70% stenosis of the circumflex artery.
What happened next.
He underwent two-vessel PCI with drug-eluting stents and was started on aggressive medical therapy including a PCSK9 inhibitor. He continued running but with appropriate monitoring. His employer estimated that preventing a potential cardiac event in a key executive — including business continuity implications — was worth many multiples of the screening cost.
Fitness does not equal cardiac health. Executive cardiac screening with advanced testing can identify significant disease that standard physicals miss, particularly in individuals with genetic risk factors.
